Details

NameSymbolSector
AAREY DRUGS & PHARMACEUTICALS LIMITEDAAREYDRUGSPharmaceuticals
Open
83
High
83
Low
82.22
Close
82.22
Volume
9087
Exchange
nse
Time
03-Oct-2025

Outlook

Score:

1

Rating:

RISKY

Candlestick Pattern

CandlepatternofAareyDrugs&Pharmaceuticalsis
Marubozu
EstimatedStoplossofAareyDrugs&Pharmaceuticalsis
83
AareyDrugs&Pharmaceuticalshasa
Bearishℹ
pattern.
Formationof
Marubozu
candlepatternindicatesAareyDrugs&Pharmaceuticalshaschancesof
Continuationℹ
ofthecurrenttrend.

Trend

AareyDrugs&Pharmaceuticalsisin
Sideways trendℹ
.
PriceofAareyDrugs&Pharmaceuticalsis
Upℹ
by

15.3

%.
Target
Buy@

58.08

Sell@

80.66

Current@

82.22

Volume

ThetradevolumesofAareyDrugs&Pharmaceuticalshavebecome
Deficientℹ
ThoughthevolumetrendforAareyDrugs&Pharmaceuticalsappears
Bullishℹ
theparticipantsseemtobe
Weak Buyersℹ
ThetradevolumeofAareyDrugs&Pharmaceuticalsis

Down

by

79.2

%

Valuation

ThecurrentmarketpriceofAareyDrugs&Pharmaceuticalsis
Overvaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth238crandtotalassetsworth238cr,thebalancesheetofAareyDrugs&Pharmaceuticalsis:
Balancedℹ
.
Cashflow
AareyDrugs&Pharmaceuticalshas
Insufficientℹ
cashflowbecauseitis

₹ 0cr

.Itis
Downℹ
by

0

%.
52.94% i.e. ₹ 9cr earned in operatingℹ
29.41% i.e. ₹ 5cr spent in investingℹ
17.65% i.e. ₹ 3cr spent in financingℹ
0% in otherℹ
AareyDrugs&Pharmaceuticalshas
Insufficientℹ
cashflowbecauseitis

₹ 0cr

.Itis
Downℹ
by

0

%.
25% i.e. ₹ 2cr spent in operatingℹ
12.5% i.e. ₹ 1cr spent in investingℹ
62.5% i.e. ₹ 5cr earned in financingℹ
0% in otherℹ
Income
TheincomeofAareyDrugs&Pharmaceuticalsis

₹ 103cr

and

Profit

is:

₹ 1cr

AareyDrugs&PharmaceuticalsProfitisupby:

100

%andIncomeisDownby:

10.43

%
TheincomeofAareyDrugs&Pharmaceuticalsis

₹ 115cr

and

Loss

is:

₹ 0cr

AareyDrugs&PharmaceuticalsLossesincreasedby:

0

%andIncomeisDownby:

14.18

%
TheincomeofAareyDrugs&Pharmaceuticalsis

₹ 134cr

and

Loss

is:

₹ 0cr

AareyDrugs&PharmaceuticalsLossesincreasedby:

100

%andIncomeisUpby:

27.62

%
By using this site you agree to the use of cookies to deliver a better site experience.